FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3166951288> ?p ?o ?g. }

• W3166951288 endingPage "4019" @default.
• W3166951288 startingPage "4019" @default.
• W3166951288 abstract "4019 Background: Results from a ph1b trial evaluating gem/NP with CD40 agonistic monoclonal antibody APX005M ± nivo demonstrated promising clinical activity in pts with untreated mPDAC (O’Hara 2021). Herein, we report results from the follow-on, randomized (rand) ph2 trial evaluating gem/NP ± nivo ± APX005M. Methods: Pts with untreated mPDAC were rand to 1 of 3 open-label arms: gem/NP/nivo (A), gem/NP/APX005M (B), gem/NP/nivo/APX005M (C). All pts were treated with 1000 mg/m 2 gem and 125 mg/m 2 NP. Patients received 240 mg nivo in arms A and C and 0.3 mg/kg APX005M (RP2D) IV in arms B and C. Ph1b pts were included in ph2 analyses. 1° endpoint: 1-year OS rate of each arm, compared to a 35% historical OS rate for gem/NP (Von Hoff 2013). Key 2° endpoints: ORR, DCR, DOR, PFS and safety. Tumor and blood were collected for biomarker analysis. Planned enrollment of 35 pts/arm provided 81% power for testing the alternative of 58% OS rate vs 35%, using a 1-sided, 1-sample Z test with 5% type I error. Trial was not powered for cross-arm comparison. Results: 93 pts were rand in ph2 (N = 34, 30, 29 to A, B, C); when ph1b pts included, a total of 105 pts (34, 36, 35) were analyzed for efficacy and 108 pts (36, 37, 35) for safety. Min follow-up was 14 months (mos). Baseline characteristics were balanced across arms, inclusive of tumor burden, presence of liver metastases and stage at initial diagnosis (stage 1-3 vs 4). 1-year OS rate was 57% (1-sided p = 0.007 vs 35% historical rate, 95% lower CI bound = 41%) for A, 51% (p = 0.029, 95% bound = 36%) for B and 41% (p = 0.236, 95% bound = 27%) for C. Median OS and secondary endpoints are listed in Table. TRAE rates were similar across arms and to ph1b. 8 (7%) pts experienced an AE leading to tx discontinuation (6, 1, 1 in A, B, C), 40 (37%) pts experienced a serious TRAE (14, 15, 11 in A, B, C) and 2 pts died due to TRAEs; 1 each in B (acute hepatic failure) and C (intracranial hemorrhage). Conclusions: In this ongoing, seamless ph1b/2 trial of gem/NP ± nivo ± APX005M in pts with mPDAC, antitumor activity was observed in all arms. 1° endpoint of 1-year OS > 35% was met when combining gem/NP with either nivo or APX005M; however, not the combination. Safety was manageable; consistent with ph1b. Detailed multiomic immune and tumor biomarker analyses are underway to elucidate mechanisms of action and inform pt subsets that benefit most from these combinations. Clinical trial information: NCT03214250. [Table: see text]" @default.
• W3166951288 created "2021-06-22" @default.
• W3166951288 creator A5011802848 @default.
• W3166951288 creator A5019473289 @default.
• W3166951288 creator A5035371911 @default.
• W3166951288 creator A5036188351 @default.
• W3166951288 creator A5036507892 @default.
• W3166951288 creator A5038924928 @default.
• W3166951288 creator A5040663360 @default.
• W3166951288 creator A5040750947 @default.
• W3166951288 creator A5042029338 @default.
• W3166951288 creator A5045990142 @default.
• W3166951288 creator A5049034795 @default.
• W3166951288 creator A5049359065 @default.
• W3166951288 creator A5052205775 @default.
• W3166951288 creator A5052264374 @default.
• W3166951288 creator A5061090388 @default.
• W3166951288 creator A5067420630 @default.
• W3166951288 creator A5070411005 @default.
• W3166951288 creator A5076438320 @default.
• W3166951288 creator A5080783554 @default.
• W3166951288 creator A5090850930 @default.
• W3166951288 date "2021-05-20" @default.
• W3166951288 modified "2023-10-16" @default.
• W3166951288 title "Gemcitabine (Gem) and nab-paclitaxel (NP) ± nivolumab (nivo) ± CD40 agonistic monoclonal antibody APX005M (sotigalimab), in patients (Pts) with untreated metastatic pancreatic adenocarcinoma (mPDAC): Phase (Ph) 2 final results." @default.
• W3166951288 doi "https://doi.org/10.1200/jco.2021.39.15_suppl.4019" @default.
• W3166951288 hasPublicationYear "2021" @default.
• W3166951288 type Work @default.
• W3166951288 sameAs 3166951288 @default.
• W3166951288 citedByCount "18" @default.
• W3166951288 countsByYear W31669512882021 @default.
• W3166951288 countsByYear W31669512882022 @default.
• W3166951288 countsByYear W31669512882023 @default.
• W3166951288 crossrefType "journal-article" @default.
• W3166951288 hasAuthorship W3166951288A5011802848 @default.
• W3166951288 hasAuthorship W3166951288A5019473289 @default.
• W3166951288 hasAuthorship W3166951288A5035371911 @default.
• W3166951288 hasAuthorship W3166951288A5036188351 @default.
• W3166951288 hasAuthorship W3166951288A5036507892 @default.
• W3166951288 hasAuthorship W3166951288A5038924928 @default.
• W3166951288 hasAuthorship W3166951288A5040663360 @default.
• W3166951288 hasAuthorship W3166951288A5040750947 @default.
• W3166951288 hasAuthorship W3166951288A5042029338 @default.
• W3166951288 hasAuthorship W3166951288A5045990142 @default.
• W3166951288 hasAuthorship W3166951288A5049034795 @default.
• W3166951288 hasAuthorship W3166951288A5049359065 @default.
• W3166951288 hasAuthorship W3166951288A5052205775 @default.
• W3166951288 hasAuthorship W3166951288A5052264374 @default.
• W3166951288 hasAuthorship W3166951288A5061090388 @default.
• W3166951288 hasAuthorship W3166951288A5067420630 @default.
• W3166951288 hasAuthorship W3166951288A5070411005 @default.
• W3166951288 hasAuthorship W3166951288A5076438320 @default.
• W3166951288 hasAuthorship W3166951288A5080783554 @default.
• W3166951288 hasAuthorship W3166951288A5090850930 @default.
• W3166951288 hasConcept C121608353 @default.
• W3166951288 hasConcept C126322002 @default.
• W3166951288 hasConcept C126894567 @default.
• W3166951288 hasConcept C141071460 @default.
• W3166951288 hasConcept C143998085 @default.
• W3166951288 hasConcept C203092338 @default.
• W3166951288 hasConcept C2777701055 @default.
• W3166951288 hasConcept C2780030458 @default.
• W3166951288 hasConcept C2780210213 @default.
• W3166951288 hasConcept C2780258809 @default.
• W3166951288 hasConcept C535046627 @default.
• W3166951288 hasConcept C71924100 @default.
• W3166951288 hasConcept C90924648 @default.
• W3166951288 hasConceptScore W3166951288C121608353 @default.
• W3166951288 hasConceptScore W3166951288C126322002 @default.
• W3166951288 hasConceptScore W3166951288C126894567 @default.
• W3166951288 hasConceptScore W3166951288C141071460 @default.
• W3166951288 hasConceptScore W3166951288C143998085 @default.
• W3166951288 hasConceptScore W3166951288C203092338 @default.
• W3166951288 hasConceptScore W3166951288C2777701055 @default.
• W3166951288 hasConceptScore W3166951288C2780030458 @default.
• W3166951288 hasConceptScore W3166951288C2780210213 @default.
• W3166951288 hasConceptScore W3166951288C2780258809 @default.
• W3166951288 hasConceptScore W3166951288C535046627 @default.
• W3166951288 hasConceptScore W3166951288C71924100 @default.
• W3166951288 hasConceptScore W3166951288C90924648 @default.
• W3166951288 hasFunder F4320315119 @default.
• W3166951288 hasIssue "15_suppl" @default.
• W3166951288 hasLocation W31669512881 @default.
• W3166951288 hasOpenAccess W3166951288 @default.
• W3166951288 hasPrimaryLocation W31669512881 @default.
• W3166951288 hasRelatedWork W114644245 @default.
• W3166951288 hasRelatedWork W1964744725 @default.
• W3166951288 hasRelatedWork W1969578744 @default.
• W3166951288 hasRelatedWork W2005537476 @default.
• W3166951288 hasRelatedWork W2319496893 @default.
• W3166951288 hasRelatedWork W2376347278 @default.
• W3166951288 hasRelatedWork W2744534349 @default.
• W3166951288 hasRelatedWork W2900510703 @default.
• W3166951288 hasRelatedWork W2973816194 @default.
• W3166951288 hasRelatedWork W2187801383 @default.
• W3166951288 hasVolume "39" @default.
• W3166951288 isParatext "false" @default.
• W3166951288 isRetracted "false" @default.

• next